Safety of systemic therapies in the treatment of psoriasis with concomitant cirrhosis: a retrospective study

Blaszczak, Alecia; Dunaway, Spencer; Alikhan, Mirza; Kelly, Sean G.; Levin, Douglas; Kaffenberger, Jessica

doi:10.1111/ijd.14556

Cited by 2 publications

(1 citation statement)

References 4 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some evidence suggests that the host’s lipid metabolism is influenced by the gut microbiota ( Blaszczak et al, 2019 ). Lipids play a crucial role in neuronal function, and the lipid composition of the brain may impact perception and emotional behavior, potentially leading to depression and anxiety ( Adibhatla and Hatcher, 2008 ; Yadav and Tiwari, 2014 ; Kornhuber et al, 2015 ).…”

Section: Metabolites In Depressionmentioning

confidence: 99%

Depression-associated gut microbes, metabolites and clinical trials

Wang,

Song,

Lai

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

Depression is one of the most prevalent mental disorders today. Over the past decade, there has been considerable attention given to the field of gut microbiota associated with depression. A substantial body of research indicates a bidirectional communication pathway between gut microbiota and the brain. In this review, we extensively detail the correlation between gut microbiota, including Lactobacillus acidophilus and Bifidobacterium longum, and metabolites such as short-chain fatty acids (SCFAs) and 5-hydroxytryptamine (5-HT) concerning depression. Furthermore, we delve into the potential health benefits of microbiome-targeted therapies, encompassing probiotics, prebiotics, and synbiotics, in alleviating depression. Lastly, we underscore the importance of employing a constraint-based modeling framework in the era of systems medicine to contextualize metabolomic measurements and integrate multi-omics data. This approach can offer valuable insights into the complex metabolic host-microbiota interactions, enabling personalized recommendations for potential biomarkers, novel drugs, and treatments for depression.

show abstract

Section: Metabolites In Depressionmentioning

confidence: 99%

Depression-associated gut microbes, metabolites and clinical trials

Wang,

Song,

Lai

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks

Massironi

Pirola

Mulinacci

et al. 2022

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Advanced therapies (biologic agents and small molecules) for inflammatory bowel diseases (IBD) have radically changed the management of these diseases during the last decade. Data about these drugs in patients with hepatic disorders derive mainly from real-life studies, as these conditions often represent an exclusion criterion from pivotal drug developmental trials. However, IBD patients sometimes have concomitant liver diseases. Nonalcoholic fatty liver disease is the most prevalent hepatic comorbidity, whereas viral hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, and hepatic vascular disorders are less frequent. This review aimed at describing the real-life data about the use of advanced therapies for IBD in patients with concomitant hepatobiliary disorders. Hepatitis B virus and hepatitis C virus infections do not represent an absolute contraindication for novel IBD therapeutic agents. Data from the literature suggest a safe hepatobiliary profile of biologic agents and small molecules in the case of nonalcoholic fatty liver disease, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, and portal vein thrombosis. Consequently, although the liver disease does not affect a different therapeutic approach in patients with concomitant IBD and liver disease, a close risk/benefit analysis for each drug should be performed in these patients, especially in cirrhotic patients and in the postliver transplant setting.

show abstract

Safety of systemic therapies in the treatment of psoriasis with concomitant cirrhosis: a retrospective study

Cited by 2 publications

References 4 publications

Depression-associated gut microbes, metabolites and clinical trials

Depression-associated gut microbes, metabolites and clinical trials

Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks

Contact Info

Product

Resources

About